(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 25 August 2005 (25.08.2005)

PCT

(10) International Publication Number WO 2005/077050 A2

(51) International Patent Classification: Not classified

(21) International Application Number:

PCT/US2005/004085

(22) International Filing Date: 10 February 2005 (10.02.2005)

(25) Filing Lunguage:

English

(26) Publication Lunguage:

English

(30) Priority Data: 60/543.670

11 February 2004 (11.02.2004) US

(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101 (US). SHIONOGI & CO., LTD [JP/JF]; 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002 (JP).

(72) Inventors; and

- Inventors/Applicants (for US only): JOHNS, Brian, Alvin [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). BOROS, Eric, Eugene [US/US]; c/o Giaxo-SmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). KAWASUJI, Takashi [JP/JP]; c/o Shionogi & Co., LTD, 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002 (JP). KOBLE, Cedila, S. [US/US]; e/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). KUROSE, Norlyuki [JP/JP]; c/o Shionogi & Co., LTD, 12-4, Sagisu 5-chome. Fukushima-ku, Osaka 553-0002 (JP), MURAI, Hitoshi [JP/JP]; c/o Shionogi & Co., LTD, 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002 (JP). SHERRILL, Ronald, George [US/US]; c/o Glaxo-SmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). WEATHERHEAD, Jason, Gordon [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709
- (74) Agents: DADSWELL, Charles, E. et al.; GlaxoSmithKline, Corporate Intellectual Property Dept., Five Moore Drive, P.O. Box 13398, Research Triungle Park, NC 27709 (US).
- (81) Designated States (unless otherwise indicated for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, BG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Burasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BB, BG, CH, CY, CZ, DE, DK, BB, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BI, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patera (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iit)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, QM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM); European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

 without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: HIV INTEGRASE INHIBITORS

2005/077050 A2

(57) Abstract: The present infention features compounds that are HIV integrase inhibitors and therefore are vseful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

AUG. 11. 2006 8:39AM GW GLOBAL R&D IS ,NO. 1389

For two-letter codes and other abbreviations, refer to the "Guldance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.